METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Immune-Boosting drug combo targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug, REGN15505, alone or with other drugs, in adults with advanced prostate or kidney cancer that has spread. The goal is to help the immune system attack cancer cells. About 265 participants will be enrolled to check safety, side effects, and …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New Dual-Action therapy targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis study tests a new approach for men with advanced prostate cancer that no longer responds to hormone therapy. It uses a special imaging agent to find cancer cells and a radioactive drug to destroy them. The goal is to see if the treatment is safe and shrinks tumors. About 49 …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Chengdu StarRay Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for advanced prostate cancer: combination therapy enters human trials
Disease control Not yet recruitingThis early-stage trial tests the safety of combining a targeted radiation drug (lutetium DGUL) with an immunotherapy (pembrolizumab) in 30 men with metastatic castration-resistant prostate cancer. Participants receive either the radiation drug alone or both drugs together. The go…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Cellbion Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could a memory drug fight prostate cancer? small trial aims to find out
Disease control Not yet recruitingThis phase 2 trial tests whether memantine hydrochloride, a drug used for Alzheimer's, can help control advanced prostate cancer that has stopped responding to standard hormone therapy. Fifteen men with metastatic castration-resistant prostate cancer will take memantine alongside…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Bin Xu • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
CBD may cut opioid need in advanced prostate cancer
Symptom relief Not yet recruitingThis study tests whether cannabidiol (CBD) can reduce the need for strong painkillers (opioids) in people with end-stage prostate cancer that has spread and no longer responds to standard treatments. About 58 participants will receive either CBD or a placebo three times daily for…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Regionshospital Nordjylland • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Real-World study eyes drug combo for tough prostate cancer
Knowledge-focused Not yet recruitingThis study observes how well a combination of two drugs, olaparib and abiraterone, works as a first treatment for men with metastatic castration-resistant prostate cancer who have already tried other hormone therapies. Researchers will track how long patients stay on the treatmen…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC